Effect of Hydrogen Gas Inhalation on Patient QOL After Hepatectomy: Protocol for a Randomized Controlled Trial

Masaki Kaibori (kaibori@hirakata.kmu.ac.jp)  
Kansai Medical University

Hisashi Kosaka  
Kansai Medical University

Study protocol

Keywords: Hydrogen inhalation, Hepatocellular carcinoma, QOL, Hepatectomy

DOI: https://doi.org/10.21203/rs.3.rs-457529/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Introduction: Molecular hydrogen had been considered inactive in vivo but is an antioxidant that selectively reduces highly toxic reactive oxygen species (ROS). Animal studies have reported that hydrogen gas inhalation helped alleviate cerebral and cardiac ischemia-reperfusion injuries. In humans, hydrogen inhalation therapy is presently approved as a treatment under Advanced Medical Care B in Japan (jRCTs031180352: limited to adult patients who suffered out-of-hospital cardiac arrest and are in a continuous coma) and its effectiveness is being examined in a clinical trial. The Japanese government has introduced the “Advanced Medical Care System” to promote the development of drugs and devices under governmental regulations. Advanced Medical Care B is a system designed for unapproved or off-label drugs or medical technologies used in a clinical trial setting. Hepatectomy is generally performed with repeated hepatic blood-flow occlusion and then reperfusion (ischemia and reperfusion). No report, however, has been made on ROS inhibition by hydrogen inhalation therapy or its effectiveness in post-hepatectomy patients. Hydrogen gas inhalation in the early stages after hepatectomy is anticipated to inhibit liver dysfunction by inhibiting ROS.

Methods and analysis: This study is a randomized, controlled, double-blind trial which will be conducted as a “specified clinical trial” in accordance with the Clinical Trials Act in Japan. The subjects will be patients who will undergo hepatectomy and will be allocated randomly into group A with hydrogen gas inhalation or group B with air inhalation after hepatectomy. The study will examine if hydrogen gas inhalation improves QOL of post-hepatectomy patients. The primary endpoint is patient QOL (score of a 40-item quality of recovery questionnaire, QoR40) on postoperative day 3 and the secondary endpoints are QoR40s besides that on postoperative day 3, grade of postoperative complications (Clavien-Dindo score), level of pain (NRS: Numerical Rating Scale), amount of dietary intake, liver function, inflammation level, 8-hydroxydeoxyguanosine (urinary 8-OHdG) level, and number of pedometer-assessed steps.

Ethics and dissemination: The protocol has been approved by the Niigata University Central Review Board of Clinical Research. The findings of this study will be disseminated widely through peer-reviewed publications and conference presentations.

Trial registration number: jRCTs No. 03220332. Approved on 21 January 2021.

Strengths And Limitations Of This Study

The present double-blind RCT is expected to show that early clinical implementation of hydrogen gas inhalation after hepatectomy will inhibit ROS, thereby inhibiting liver dysfunction.

Furthermore, hydrogen gas inhalation might be shown to contribute to early recovery of post-hepatectomy patients.

Introduction
Molecular hydrogen had been considered inactive in vivo but is an antioxidant that selectively reduces highly toxic reactive oxygen species (ROS). In 2007, a rat study reported that hydrogen gas inhalation alleviated cerebral ischemia-reperfusion injuries [1]. Focal ischemia was produced by mild occlusion of the middle cerebral artery for 90 min, followed by reperfusion for 30 min. The rats inhaled 1–4% hydrogen gas mixed with inhalation anesthetics during the entire 120-min process. After one day, the infarct volume markedly decreased due to hydrogen gas inhalation. After one week, neurological symptoms improved, as indicated by improved motor function, and oxidative stress was reduced, as indicated by reduced 8-OHdG level near the infarct site.

There have been many reports on the inhibitory effect of hydrogen gas inhalation on ischemia-reperfusion injury in organs other than brain [2, 3]. In rats, hydrogen gas inhalation reduced the cardiac infarct volume after coronary-artery ischemia and reperfusion, and cardiac function was protected [4]. Similar effects have also been reported in pigs [5]. Presently, hydrogen gas inhalation is approved as a treatment in Japan under Advanced Medical Care B (jRCTs031180352: limited to adult patients who suffered out-of-hospital cardiac arrest and are in a continuous coma), and its effectiveness is being examined in a clinical trial.

Hepatectomy is generally performed with repeated hepatic blood-flow occlusion and then reperfusion (ischemia and reperfusion). No report, however, has been made on ROS inhibition by hydrogen inhalation therapy or its clinical effectiveness in post-hepatectomy patients. Hydrogen gas inhalation in the early stages after hepatectomy is anticipated to inhibit liver dysfunction by inhibiting ROS.

**Methods/design**

This study is a randomized, controlled, double-blind trial which will be conducted as a “specified clinical trial” in accordance with the Clinical Trials Act in Japan. The study will involve 68 patients with hepatobiliary disease and who are planned to undergo hepatectomy. The trial participation period starts after consent attainment and ends at postoperative hospital discharge. The subjects will be allocated randomly into group A (hydrogen gas inhalation group: 34 subjects) and group B (air inhalation group: 34 subjects). Groups A and B will receive 1200 ml/m hydrogen gas and 1200 ml/m air, respectively, via nasal cannula. The respective gas will be administered at least one hour per time and three times per day, totaling 8 hours or less. If a subject will require oxygen, it will be administered via an oxygen mask placed over the nasal cannula. The trial participation period starts after consent attainment and ends at postoperative hospital discharge. The period is expected to be approximately 14–21 days based on our previous experience. The 40-item quality of recovery questionnaire (QoR40) will be used to assess postoperative QOL [6]. The questionnaire will be distributed preoperatively to patients who will independently fill it out themselves. The results will be totaled (perfect score: 200 points) to evaluate postoperative patient satisfaction and recovery level (reference material in the appendix at the end of this paper). The questionnaire survey will be conducted at 10 AM on postoperative day 3.
The results of previous reports infer that hydrogen gas inhalation has wide effects on many aspects, such as on inflammation and liver function, by inhibiting ROS [1–5, 7–10]. The primary endpoint, therefore, is established as the QoR40 on postoperative day 3.

**Sample size estimation**

In the field of this study, the QoR40 is constructed from 40 items related to “physical comfort,” “emotional state,” “physical independence,” “psychological support” and “pain.” The maximum score per item is 5 points and the perfect total score, therefore, is 200 points [6]. In hemodialysis patients, it has been reported that symptoms of fatigue were reduced by approximately 30% using a dialysate containing dissolved molecular hydrogen [11]. Molecular hydrogen might affect particularly “physical comfort” and “emotional state” among the 20 items of the QoR40. The results will be considered clinically meaningful if hydrogen gas inhalation is to improve the items of “physical comfort” and “emotion state” by approximately 20%. If such improvement in scores occurs, the hydrogen gas inhalation group will be estimated to score approximately 16 points more than the air inhalation group and to have an average of approximately 153 points. If factors, such as feasibility, are considered, the estimated average of the hydrogen inhalation group will be 151 points, that of the non-hydrogen inhalation group 137 points, and variance of data 30 points (same in both groups). If α-error and power are set at 0.20 and 70%, respectively, for a two-sided test, then 31 subjects per group (total of 62 subjects) will need to be enrolled in this study. If it is estimated that approximately 10% of the subjects will drop out, the target number of subjects will be 68.

**Recruitment**

The recruited subjects will be patients who provide a written consent of their own free will to participate after being fully informed of and fully understanding the study.

**Inclusion criteria**

1. Male or female aged 20 or older at the time of consent
2. Patients with hepatobiliary disease and will be undergoing hepatectomy
   - Laparotomic or laparoscopic hepatectomy
   - Any extent of liver resection
   - Any hepatobiliary disease (including hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and metastatic liver cancer)
3. Patients who provide a written consent of their own free will to participate after being fully informed of and fully understanding the study

**Exclusion criteria**

Patients who meet any of the following criteria will not be enrolled in this study:
1. Patients with severe liver dysfunction or severe kidney dysfunction

(Patients satisfying any of the following: total serum bilirubin>3.6 mg/dL, AST>175 U/L, ALT>175 U/L, creatinine>3 mg/dL, or eGFR<30 ml/min/1.73m²)

2. Poorly controlled diabetes

3. Female patients who are or might become pregnant

4. Female patients who are lactating

5. Patients who received another test drug or investigational drug within 3 months of consent

6. Patients who might undergo resection of an organ besides the liver (including stomach, colon, and lung but excluding gall bladder) at the time of hepatectomy

7. Patients who will require biliary tract reconstruction at the time of hepatectomy

8. Patients who will undergo emergency surgery (including for ruptured liver tumor)

9. Patients whom the principal investigator determined to be unsuitable for the study

**Randomization and allocation concealment**

After patient consents are obtained, web-based registration and minimization method of random allocation will be performed. Then the registration numbers and the allocation results will be added to the eligibility criteria checklist. The information will be faxed to the data center, resulting in patient registration.

**Blinding**

In this double-blind trial, the device that supplies air is manufactured so that it is indistinguishable by appearance from the hydrogen gas generator. Patient allocation was known only to the person responsible for statistical analysis, the person in charge of support for the research and development program, and the principal investigator.

**Interventions and data collection**

From postoperative day 1 to day 7, groups A and B (34 subjects each) will receive 5% hydrogen gas and air, respectively, via nasal cannula for at least one hour per time and three times per day, totaling 8 hours or less. If a subject will require oxygen, it will be administered via an oxygen mask placed over the nasal cannula (Fig. 1). Study schedule was summarized in Table 1.
**Table 1. Study schedule**

| Category                                      | Pre-treatment observation period | Day of surgery | Time of study gas administration | Post-treatment observation period |
|-----------------------------------------------|----------------------------------|----------------|----------------------------------|----------------------------------|
| Time period                                   | 1 week preoperatively – day before surgery | Day of surgery | Postoperative day 1 | Postoperative day 3 | Postoperative day 5 | Postoperative day 7 | Completion (discontinuance) at discharge |
| Informed consent                              | ●                                |                |                                  |                                  |                                  |                                  |                                      |
| Verification of patient characteristics       | ●                                |                |                                  |                                  |                                  |                                  |                                      |
| Study gas administration                      |                                  |                |                                  |                                  |                                  |                                  |                                      |
| Blood pressure and heart rate measurement    | ● ● ● ● ●                         |                |                                  |                                  |                                  |                                  |                                      |
| Weight measurement                           | ●                                |                |                                  |                                  |                                  |                                  |                                      |
| QoR40                                         | ●                                |                |                                  |                                  |                                  |                                  |                                      |
| Observation for adverse events                |                                  |                |                                  |                                  |                                  |                                  |                                      |
| Postoperative complication                    |                                  |                |                                  |                                  |                                  |                                  |                                      |
| Wound pain                                    | ● ● ● ● ●                         |                |                                  |                                  |                                  |                                  |                                      |
| Amount of dietary intake                      | ●                                |                |                                  |                                  |                                  |                                  |                                      |
| Number of pedometer-assessed steps            | ●                                |                |                                  |                                  |                                  |                                  |                                      |
| Blood tests*                                  | ● ● ● ● ●                         |                |                                  |                                  |                                  |                                  |                                      |
| Urinalysis                                    | ●                                |                |                                  |                                  |                                  |                                  |                                      |

QoR40 The 40-item quality of recovery questionnaire

**Table 2.**
| **Primary Registry and Trial Identifying Number** | Japan Registry of Clinical Trial (jRCT): No. 03220332 |
|-----------------------------------------------|-----------------------------------------------------|
| **Date of Registration in Primary Registry**  | Approved on 21 January 2021.                         |
| **Secondary Identifying Numbers**             | Niigata University Central Review Board of Clinical Research: SP20004 |
| **Source of Monetary or Material Support**    | Helix Japan K.K.                                     |
| **Primary Sponsor**                           | Helix Japan K.K.                                     |
| **Secondary Sponsor(s)**                      | None                                                |
| **Contact for Public Queries**                | Masaki Kaibori MD., PhD. Professor                  |
|                                              | Department of Surgery, Kansai Medical University     |
|                                              | Email: kaibori@hirakata.kmu.ac.jp                    |
|                                              | Postal address: 2-5-1 Shinmachi, Hirakata city, Osaka, Japan. 573-1010 |
|                                              | TEL: +81-72-804-0101                                 |
| **Contact for Scientific Queries**            | Same as above                                       |
| **Public Title**                              | Effect of inhalation of hydrogen gas on postoperative recovery |
| **Scientific Title**                          | Effect of inhalation of hydrogen gas on post-hepatectomy recovery |
|                                              | Double-blind randomized controlled trial             |
| **Countries of Recruitment**                  | Japan                                               |
| **Health Condition or Problem Studied**       | Hepatobiliary diseases                              |
| **Intervention(s)**                           | Inhalation of hydrogen gas                          |
| **Key Inclusion and Exclusion Criteria**      | Inclusion criteria:                                 |
|                                              | 1. 20 years old and elder (regardless of gender)    |
|                                              | 2. Patient who undergone hepatic resection for hepatobiliary cancer (regardless of operative procedure, range of hepatectomy and primary disease) |
|                                              | 3. patient who accept entry to this study with free will after sufficient exposition |
|                                              | Exclusion criteria:                                 |
|                                              | 1. Severe liver dysfunction or severe renal dysfunction |
2. Uncontrollable diabetes mellitus
3. Pregnancy or possibility of being pregnant
4. Lactating patient
5. Patient who received another test agent or investigational agent within three months prior to agreement for this study
6. Patient who require combined other organ resection (Stomach, Colon, Lung and so on)
7. Patient who required biliary tract reconstruction
8. Patient who required emergency surgery (HCC rupture)
9. Patient who is considered as inadequate by principal investigator of this study

| Study Type                      | Interventional, randomized controlled trial/ double blind/ placebo control/ parallel assignment/ treatment purpose |
|--------------------------------|-------------------------------------------------------------------------------------------------------------|
| Date of First Enrollment       | 9\text{th} March 2021                                                                                        |
| Sample Size                    | 68                                                                                                          |
| Recruitment Status             | Recruiting                                                                                                  |
| Primary Outcome                | QoR40 of postoperative day 3                                                                                |
| Key Secondary Outcomes         | 1. QoR40 except postoperative day3                                                                           |
|                                | 2. Postoperative complications (Clavien-Dindo score)                                                        |
|                                | 3. Wound pain (Numerical rating scale)                                                                       |
|                                | 4. Dietary intake                                                                                            |
|                                | 5. The number of steps taken                                                                                 |
|                                | 6. Inflammatory response (WBC, CRP, neutrophils, lymphocyte)                                                 |
|                                | 7. Live functions (Total bilirubin, AST, ALT, ALP, Albumin, thrombocyte, PT, ICG)                           |
|                                | 8. Reactive oxygen value (urinary 8-OHdG)                                                                    |
|                                | 9. Adverse event                                                                                            |
|                                | 10. Time of inhalation of hydrogen gas                                                                        |
| Ethics Review                  | Approved                                                                                                    |
|                                | Approved number: SP20004                                                                                     |
|                                | Date of approval: 19\text{th} January 2021                                                                   |
1. QoR40 scores: Subjects will fill out the previously distributed questionnaire preoperatively, on postoperative days 3 and 7, and at discharge. The questionnaire will be collected by the attending nurse. The primary endpoint is the QoR40 on postoperative day 3.

2. Grade of postoperative complications (Clavien-Dindo score): The attending physician will evaluate on the day of discharge [12].

3. Level of pain (Numerical rating scale: NRS): The attending nurse will record it in the medical record on postoperative days 1, 3, 5, and 7 and on the day of discharge.

4. Amount of dietary intake: The attending nurse will record it in the medical record preoperatively, on postoperative days 3, 5, and 7 and on the day of discharge.

5. Number of pedometer-assessed steps: The number of steps per day will be measured using a pedometer preoperatively and on postoperative days 3, 5, and 7. The attending nurse will record the numbers in the medical record.

6. Inflammatory response (white blood cell count, differential white blood cell count, and lymphocyte count): They will be measured preoperatively, on postoperative days 0, 1, 3, 5, and 7, and on the day of discharge. They will be automatically recorded in the medical record.

7. Liver function (T-Bil, AST, ALT, ALP, albumin, PT, and ICG): The ICG test will be performed only one time, namely preoperatively. Other measurements will be made preoperatively and on postoperative days 0, 1, 3, 5, and 7, and on the day of discharge. All measurements will be automatically recorded in the medical record.

8. Reactive oxygen level (urinary 8-OHdG level): A subinvestigator will measure preoperatively, on postoperative days 3 and 7, and on the day of discharge and then will record the measurements in the case report form.

9. Adverse events: Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

10. Duration of study gas inhalation (measured per 24 hours and totaled by week)

**Primary endpoint**
The postoperative recovery level (QoR40) on postoperative day 3 will be evaluated to examine the effectiveness of the hydrogen gas inhalation treatment. The QoR40 will be measured using a questionnaire on postoperative QOL which will be distributed preoperatively. Each patient will independently fill out the questionnaire himself/herself. The scores will be totaled (perfect score: 200 points), and the resulting number will be evaluated as the patient satisfaction level and recovery level. The questionnaire survey will be conducted at 10 AM on postoperative day 3.

The results of previous reports infer that hydrogen gas inhalation has wide effects on many aspects, such as on inflammation and liver function, by inhibiting ROS. The primary endpoint, therefore, is established as the QoR40 on postoperative day 3. A subinvestigator will record the results of the questionnaire in the case report form after the patient is discharged.

**Secondary endpoints**

Data on the following items will be collected chronologically during the study period and comprehensive and exploratory evaluations will be performed.

1. QoR40s besides that on postoperative day 3
2. Grade of postoperative complications (Clavien-Dindo score): The attending physician will record it in the medical record at discharge.
3. Level of pain (NRS): The attending physician or attending nurse will record it in the medical record after interviewing the patients.
4. Amount of dietary intake: The amount of dietary intake is assessed at breakfast, lunch, and dinner, and 100% is a completely eaten meal. The attending nurse will visually determine the amount of uneaten food to evaluate the amount of dietary intake and will record it in the medical record.
5. Number of pedometer-assessed steps: The number of steps per day will be measured using a pedometer, and the attending nurse will confirm it and record it in the medical record.
6. Inflammatory response (WBC, CRP, neutrophil count, and lymphocyte count): They will be automatically recorded in the medical record.
7. Liver function (T-BIL, AST, ALT, ALP, albumin, platelet count, PT, and ICG): All measurements will be automatically recorded in the medical record.
8. Reactive oxygen level (urinary 8-OHdG* level): *This level reflects the level of oxidative damage to DNA caused by excessive reactive oxygen species. A subinvestigator will measure it and will record it in the case report form.
9. Adverse events: CTCAE version 5.0.

A subinvestigator will enter the aforementioned medical-record data in the case report form after discharge.

**Safety evaluation**
No clinical trial has previously reported any side effects of hydrogen gas inhalation. In this trial, however, the administration of study gas will be immediately discontinued if any serious adverse event occurs.

All adverse events will be recorded and serious adverse events will be totaled separately. If adverse events occur after study gas administration, they will be totaled separately for group A and group B. In addition, the number of patients who experienced the adverse event, number of adverse event episodes, and incidence of adverse events will be determined, and comparison will be made between groups A and B. All adverse events will be examined regardless of causal relationship.

Descriptive statistics will be used for clinical test results for each of group A and B, and clinically significant changes will be totaled. For other parameters, descriptive statistical values will be calculated by group according to the variable type (continuous or categorical variable), or frequencies will be totaled.

**Statistical analysis**

For the primary analysis, an unpaired t-test with common variance (PPS analysis) will be performed to compare the mean of the QoR40 on postoperative day 3 between groups. The subject population to be analyzed will consist of patients who will have consented to trial participation; who will have been administered, according to schedule, at least the minimum dose of their respective gas for at least 2 days; and whose QoR40 on postoperative day 3 will have been measured. The daily minimum dose will be converted to the duration of administration (3-hr duration per day) and will be administered in at least 6 hours to less than 7 hours. In the sensitivity analysis, a t-test will be used on the per-protocol population and similarly on a population which includes patients who received insufficient gas. Content with a focus on the non-unique content will be noted in a statistical analysis plan. No compensation for missing data will be made. The statistical significance level will be set at 5% (two-sided) with a confidence interval of 95% (two-sided). No interim analysis will be performed.

For other items, the effects of hydrogen inhalation will be examined by parameters, such as the extent of hepatectomy (segmentectomy or more extensive resection vs subsegmentectomy or less extensive resection) and hepatic ischemia time (30 min or more vs less than 30 min). In addition, comprehensive and exploratory examinations will be performed, including comparison of patients with high QoR40 scores and patient characteristics.

**Analysis of efficacy**

The measure of efficacy of the primary endpoint is the improvement of the QoR40 of the per-protocol population on postoperative day 3. The primary subject population for analysis will be the per-protocol population, but analysis of the intention-to-treat population will also be performed to evaluate the potential for practical application.

**Data monitor**
All records related to the clinical trial, including source documents, will be available for trial-related monitoring and inspections by the certified review board and regulatory authorities.

**Declarations**

**Ethics and dissemination**

Hepatectomy is generally performed with repeated hepatic blood-flow occlusion and then reperfusion. In mice, liver injuries have been known to be caused by ROS generated in the body due to liver ischemia and reperfusion [8]. In a human clinical study, post-hepatectomy ROS has been reported to increase approximately threefold in post-hepatectomy patients with serious postoperative complications of Clavien-Dindo IIIa or more severe compared with those without serious postoperative complications [9]. In an animal study, mice underwent hepatic portal vein ligation and liver excision after ischemia-reperfusion, and impairment was evaluated. The study showed that hydrogen gas inhalation inhibited ROS production, liver-tissue injuries, and elevation of serum ALT [10]. No report, however, has been made on ROS inhibition by hydrogen inhalation therapy or its clinical effectiveness in post-hepatectomy patients. The present double-blind RCT is expected to show that early clinical implementation of hydrogen gas inhalation after hepatectomy (after liver ischemia-reperfusion) will inhibit ROS, thereby inhibiting liver dysfunction. Furthermore, hydrogen gas inhalation might be shown to contribute to early recovery of post-hepatectomy patients.

**Trial status**

The trial is proceeding according to the protocol (version 2.0, 19 November 2020). There will be a total of 68 candidates for study subjects with hepatobiliary disease, for which hepatectomy will be planned at the Kansai Medical University Hospital from protocol approval until 31 December 2022.

**Study timeline**

Total study period: Japan Registry of Clinical Trial (jRCT) publication day – 2023 December 31

Enrollment period: jRCT publication day – 2022 December 31

**Ethics approval and consent to participate**

This study was approved by the certified review board, the Niigata University Central Review Board of Clinical Research.

**Registration No.** jRCTs No. 03220332

**Consideration of participants’ human rights, safety and disadvantages**
This trial will not use personal information that could immediately identify the subject (including name, address, and phone number) in handling of specimens and information related to the trial. The specimens and information, instead, will be anonymized. Oversight of the principal investigator will be performed to ensure that the registration numbers of subjects are securely stored for privacy protection. Information that can identify the subjects are not included in information that will be obtained from this trial and that will be published by individuals such as the principal investigator. In addition, specimens and information of subjects obtained in this study will not be used for purposes other than for this study. Patients that are enrolled into this trial are covered by indemnity for negligent harm through the standard national health insurance. This trial has insurance to cover for non-negligent harm associated with the protocol.

**Funding**

Helix Japan K.K. will provide the hydrogen gas generator free of charge and will provide the research funding for this study. The researchers, however, have planned and will conduct this study independently from Helix Japan, which will not be involved in the conducting, analyzing, or reporting of the study.

Contact information of Helix Japan: YKB Shinjyuku-Gyoen 201, 1-3-8 Shinjyuku, Tokyo, 160-0022. Japan

**Patient consent for publication**

Written informed consent was provided by all patients.

**Availability of data and materials**

For protection of privacy of participants, the datasets analyzed during the current study have not been made publicly available, but they can be obtained from the corresponding authors if there are reasonable requirements.

**Authorship**

Topics suggested for presentation or publication will be circulated to the principal investigators and the data coordinating center. Both groups are requested to suggest and justify names for authors to be reviewed by the publications committee.

**Authors’ contributions**

MK and HK made substantial contributions to the conception and design of this study. MK drafted the manuscript. All the authors provided critical review and final approval of the present manuscript.

**Acknowledgements**

We thank all researchers for their efforts to participate in this trial and recruit and treat participants.

**Competing interests**
The authors declare that they have no competing interests.

**WHO Trial Registration Data Set**

Trial date were summarized in Table 2 according to WHO Trial Registration Data Set manner.

**References**

1. Ohsawa I, Ishikawa M, Takahashi K, et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat Med. 2007;13(6):688–94. doi:10.1038/nm1577.

2. Buchholz BM, Kaczorowski DJ, Sugimoto R, et al. Hydrogen inhalation ameliorates oxidative stress in transplantation induced intestinal graft injury. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2008;8(10):2015–24. doi:10.1111/j.1600-6143.2008.02359.x.

3. Nakao A, Kaczorowski DJ, Wang Y, et al. Amelioration of rat cardiac cold ischemia/reperfusion injury with inhaled hydrogen or carbon monoxide, or both. J Hear lung Transplant Off Publ Int Soc Hear Transplant. 2010;29(5):544–53. doi:10.1016/j.healun.2009.10.011.

4. Hayashida K, Sano M, Ohsawa I, et al. Inhalation of hydrogen gas reduces infarct size in the rat model of myocardial ischemia-reperfusion injury. Biochem Biophys Res Commun. 2008;373(1):30–5. doi:10.1016/j.bbrc.2008.05.165.

5. Sakai K, Cho S, Shibata I, Yoshitomi O, Maekawa T, Sumikawa K. Inhalation of hydrogen gas protects against myocardial stunning and infarction in swine. Scand Cardiovasc J. 2012;46(3):183–9. doi:10.3109/14017431.2012.659676.

6. Shida D, Wakamatsu K, Tanaka Y, et al. The postoperative patient-reported quality of recovery in colorectal cancer patients under enhanced recovery after surgery using QoR-40. BMC Cancer. 2015;15(1):1–6. doi:10.1186/s12885-015-1799-3.

7. Ohsawa I. Physiological function of molecular hydrogen and therapeutic benefits of hydrogen-enriched water. Jpn J Geriat. 2012;49:680–8. doi:10.1017/CBO9781107415324.004. [in Japanese].

8. Yamazoe S, Uchiyama K, Nakatani Y, Tanimura H. Hydroxyl radical and nitric oxide generation following ischemia-reperfusion injury of rabbit liver. Japanese Journal of Surgical Metabolism Nutrition. 2000;34(6):269–82. [in Japanese].

9. Schwarz C, Fitschek F, Bar-Or D, et al. Inflammatory response and oxidative stress during liver resection. PLoS One. 2017;12(10):1–14. doi:10.1371/journal.pone.0185685.

10. Fukuda K, Asoh S, Ishikawa M, Yamamoto Y, Ohsawa I, Ohta S. Inhalation of hydrogen gas suppresses hepatic injury caused by ischemia/reperfusion through reducing oxidative stress. Biochem Biophys Res Commun. 2007;361(3):670–4. doi:10.1016/j.bbrc.2007.07.088.

11. Nakayama M, Nakano H, Hamada H, Itami N, Nakazawa R, Ito S. A novel bioactive haemodialysis system using dissolved dihydrogen (H2) produced by water electrolysis: a clinical trial. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2010;25(9):3026–33. doi:10.1093/ndt/gfq196.
12. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13. doi:10.1097/01.sla.0000133083.54934.ae.

**Supplemental**

The appendix is not provided with this version.